Evidence map›Paper›PMID 32774235›Full record

ArticleCurrent urology2020

Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma.

Alessio Cortellini, Sebastiano Buti, Melissa Bersanelli, Katia Cannita, Giada Pinterpe, Olga Venditti, Lucilla Verna, Giampiero Porzio, Clara Natoli, Nicola Tinari and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study.International journal of urology : official journal of the Japanese Urological Association · 2022
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alessio CortelliniMedical Oncology Unit, St. Salvatore Hospital, L'Aquila.
Sebastiano ButiMedical Oncology Unit, University Hospital of Parma, Parma.
Melissa BersanelliMedical Oncology Unit, University Hospital of Parma, Parma.
Katia CannitaMedical Oncology Unit, St. Salvatore Hospital, L'Aquila.
Giada PinterpeMedical Oncology Unit, St. Salvatore Hospital, L'Aquila.
Olga VendittiMedical Oncology Unit, St. Salvatore Hospital, L'Aquila.
Lucilla VernaDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila.
Giampiero PorzioMedical Oncology Unit, St. Salvatore Hospital, L'Aquila.
Clara NatoliDepartment of Medical, Oral and Biotechnological Sciences, University G. D'Annunzio, Chieti.
Nicola TinariDepartment of Medical, Oral and Biotechnological Sciences, University G. D'Annunzio, Chieti.
Luca CindoloDepartment of Urology, ASL 2 Abruzzo, Hospital "S. Pio da Pietrelcina", Vasto.
Luigi Di ClementeDepartment of Urology, St. Salvatore Hospital, L'Aquila, Italy.
Antonino GrassadoniaDepartment of Medical, Oral and Biotechnological Sciences, University G. D'Annunzio, Chieti.
Michele De TursiDepartment of Medical, Oral and Biotechnological Sciences, University G. D'Annunzio, Chieti.
Corrado FicorellaMedical Oncology Unit, St. Salvatore Hospital, L'Aquila.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, the GRANT (GRade, Age, Nodes, and Tumor) score was validated through an adjuvant trial population.

methodsThis retrospective study evaluated the performance of the GRANT score as a prognostic model for disease-free survival (DFS), compared to the University of California Los Angeles Integrated Staging System (UISS) score, in a "real-life" population of early renal cell carcinoma patients. A uni-/multivariate analysis of DFS was also performed, to weigh the roles of baseline clinical factors.

resultsFrom February 1998 to January 2018, 134 consecutive patients were enrolled, of which 85 patients (63.4%) had a favorable GRANT score, 49 (36.6%) an unfavorable GRANT score, and 21 (15.7%), 84 (62.6%), and 29 (21.6%) patients had a low, intermediate, or high risk of recurrence according to the UISS score, respectively. The median follow-up was 96 months. The median DFS of the overall study population was 53.7 months (95% CI: 38.4-87.8). Only bilateral renal cell carcinoma (p = 0.0041), Fuhrman grade 3/4 (p = 0.0008), pT3b- 4 (p = 0.0324), and pN1-2 (p = 0.0303) pathological status were confirmed as independent predictors of a shorter DFS by the multivariate analysis. The median DFS of patients with favorable and unfavorable GRANT scores were 84.9 (95% CI: 49.8-129) and 38.4 months (95% CI: 24.4-87.8), respectively, with a statistically significant difference (p = 0.0147). The median DFS of patients with low, intermediate, and high risk of recurrence according to the UISS score were 92.3 (95% CI: 18.1-153.9), 51.7 (95% CI: 36.2-87.8), and 49.8 months (95% CI: 31.3-129), respectively, without statistically significant differences (p = 0.4728). DFS c-statistic values were 0.59 (95% CI: 0.51-0.67) and 0.51 (95% CI: 0.42-0.60) for the GRANT and the UISS scores, respectively.

conclusionThe GRANT score might be a useful tool that is user-friendly and easy to perform in clinical practice.

Indexed as

Disease-free survivalGRANTKidneyPredictive modelRenal cell carcinoma

Identifiers

PMID32774235
PMCPMC7390980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.